Treating Obstructive Sleep Apnea May Slow Age-Related Cognitive Decline

The study involved 500 non-obese adult males who underwent comprehensive sleep assessments and cognitive testing at baseline and follow-up visits. These findings have important implications for public health, as OSA is a common sleep disorder that affects up to 30% of adults the world over, all while cognitive decline is a major concern for aging populations.

Fortunately, the study also suggests that treating obstructive sleep apnea may have beneficial effects on cognitive function. However, the early detection and treatment of OSA can be challenging, given the current limitations of traditional sleep testing methods.

Polysomnography (PSG) is considered the gold standard for diagnosing OSA, but it can be time-consuming, expensive, and uncomfortable for patients. Moreover, PSG testing may not capture the full spectrum of OSA symptom severity and variability since it only measures sleep during a single night in a controlled laboratory environment setting. This can lead to underdiagnosis or misdiagnosis of OSA and have serious health consequences if left untreated.

To overcome these limitations, Neurobit offers a range of products that can reduce the time and cost associated with traditional sleep testing methods and enable earlier detection and treatment of OSA.

Neurobit Score is a PSG and home sleep test (HST) AI and deep learning cloud-based scoring platform that accurately labels sleep events with real-time scoring capability.

Z3 Pulse is an ECG-based chest wearable device that works with NeurobitScore to provide sleep reports and guidance for improving sleep. Neurobit Hub is a one-stop-shop research and academia-oriented platform for gathering and analyzing large datasets with convenient zero-click integration.

NeurobitHub is customizable and can help facilitate the research and discovery of novel biomarkers.

The study highlights the importance of early detection, diagnosis, and treatment of OSA. Our technological advancements here at Neurobit have the potential to reduce the time and cost associated with traditional sleep testing methods and enable earlier detection and treatment of OSA, and contribute to the prevention and management of OSA to potentially slow down age-related cognitive decline.

Reach out if you would like to find out more, try our technology, work with us, and ultimately help us accelerate the development of innovative technologies for the early detection and treatment of disorders, such as OSA, to improve health for all. Email us at Research@Neurobit.com

Citation:

Gnoni, V., Mesquita, M., O’Regan, D., Delogu, A., Chakalov, I., Antal, A., Young, A. H., Bucks, R. S., Jackson, M. L., & Rosenzweig, I. (2023). Distinct cognitive changes in male patients with obstructive sleep apnoea without co-morbidities. Frontiers in Sleep, 2, 1097946. https://doi.org/10.3389/frsle.2023.1097946